Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.40 |
| ▸ | ADH1B | P00325 | 3/20 | 0.39 |
| ▸ | ADH1C | P00326 | 3/20 | 0.39 |
| ▸ | ADH1A | P07327 | 3/20 | 0.39 |
| ▸ | ADH7 | P40394 | 3/20 | 0.39 |
| ▸ | ADH4 | P08319 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927982 | 1.00 | TSHR (0.43) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL25492666 | 1.00 | TSHR (0.43) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL7770644 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL7775229 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL18596246 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL11150782 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL19006418 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL25100338 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Hydrochloric Acid SCHEMBL22575381 | 0.98 | TSHR (0.42) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL25588095 | 0.98 | EPHX1 (0.44) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104024258-B | Pyrrolopyrazine kinase inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-02-15 | — | — | CN | claimed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20210188763-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | UNIV CALIFORNIA (US) | 2021-06-24 | — | — | US | disclosed |
| US-10822299-B2 | Compounds and methods for hematopoietic regeneration | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3717450-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | The Regents of the University of California (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190292132-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-09-26 | — | — | US | disclosed |
| EP-3464236-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | The Regents of the University of California (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205795-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20080279500-A1 | Method for Producing J Aggregates | CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECH (CH) | 2008-11-13 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| WO-1998037078-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES | NOVO NORDISK A/S (DK) | 1998-08-27 | — | — | WO | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188763-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | HGF, CXCL12, CCL11 | TSHR 4417/4885ALDH1A1 514/4885EPHX1 144/4885 |
| US-20190292132-A1 | COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION | HGF, CXCL12, CCL11 | TSHR 4417/4885ALDH1A1 514/4885EPHX1 144/4885 |
| US-10822299-B2 | Compounds and methods for hematopoietic regeneration | HGF, CXCL12, CCL11 | TSHR 4417/4885ALDH1A1 514/4885EPHX1 144/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | TSHR 3398/4885ALDH1A1 3447/4885EPHX1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.